Trial Profile
An Open Label, Phase I Study of Copanlisib to Evaluate the Pharmacokinetics, Safety and Tolerability in Chinese Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jun 2022
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors Bayer
- 01 Jun 2022 Results published in the Cancer Chemotherapy and Pharmacology
- 29 Sep 2020 Status changed from active, no longer recruiting to completed.
- 20 Apr 2020 Planned End Date changed from 3 Apr 2020 to 30 Nov 2020.